(Q44371252)

2 December 2017

title

Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials (English)

1 reference

2 December 2017

Bruce J Kinon

1

1 reference

2 December 2017

Julie A Gilmore

series ordinal

2

1 reference

2 December 2017

Hong Liu

series ordinal

3

1 reference

2 December 2017

Uriel M Halbreich

series ordinal

4

1 reference

2 December 2017

publication date

1 April 2003

1 reference

2 December 2017

published in

Psychoneuroendocrinology

1 reference

2 December 2017

volume

28 Suppl 2

1 reference

2 December 2017

page(s)

69-82

1 reference

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Endogenous hormones and breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Asymptomatic hyperprolactinemia resulting from macroprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Hyperprolactinemia and male sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Negative symptoms in schizophrenia: neurobiological models and treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

The prolactin response to intravenous dextroamphetamine in normal young men and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Clozapine: plasma levels and prolactin response

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

A study of serum prolactin levels in schizophrenia: comparison of males and females

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine☆

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Clozapine does not elevate serum prolactin levels in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Medical treatment of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900128-2

7 January 2021

10.1016/S0306-4530(02)00128-2

Identifiers

DOI

1 reference

2 December 2017

1 reference